PFE Debt / Equity | PFIZER INC

PFIZER INC Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

PFIZER INC debt/equity ratio for the quarter ending 2026-06-28 was 0.74, a 6.40% increase year-over-year.
PFIZER INC debt/equity ratio for the quarter ending 2026-03-29 was 0.71, a 5.22% increase year-over-year.
PFIZER INC debt/equity ratio for the quarter ending 2025-12-31 was 0.74, a 7.80% increase year-over-year.
PFIZER INC debt/equity ratio for the quarter ending 2025-09-28 was 0.66, a 0.73% decline year-over-year.
PFIZER INC debt/equity ratio for fiscal 2025 was 0.74, a 7.80% increase from fiscal 2024.
PFIZER INC debt/equity ratio for fiscal 2024 was 0.69, a 3.28% decline from fiscal 2023.
PFIZER INC debt/equity ratio for fiscal 2023 was 0.71, a 93.34% increase from fiscal 2022.
PFIZER INC debt/equity ratio for fiscal 2022 was 0.37, a 24.34% decline from fiscal 2021.

Available history: 2008-12-31 to 2026-06-28
Data captured: 2026-06-28

Historical Debt/Equity Ratio

Date	Debt/Equity Ratio	Long-term debt	Shareholder equity
2026-06-28	0.74	$63.1B	$85.49B
2026-03-29	0.71	$64.43B	$90.4B
2025-12-31	0.74	$64.64B	$86.78B
2025-09-28	0.66	$61.66B	$93.1B
2025-06-29	0.69	$61.75B	$89.01B
2025-03-30	0.68	$61.39B	$90.64B
2024-12-31	0.69	$61.15B	$88.5B
2024-09-29	0.67	$61.75B	$92.56B
2024-06-30	0.7	$61.25B	$87.98B
2024-03-31	0.67	$62.31B	$92.56B
2023-12-31	0.71	$63.79B	$89.29B
2023-10-01	0.65	$63.31B	$97.2B
2023-07-02	0.65	$64.92B	$99.29B
2023-04-02	0.35	$35.27B	$101.24B
2022-12-31	0.37	$35.44B	$95.92B
2022-10-02	0.38	$35.2B	$92.89B
2022-07-03	0.41	$35.57B	$87.47B
2022-04-03	0.43	$35.92B	$82.69B
2021-12-31	0.49	$37.83B	$77.46B
2021-10-03	0.51	$38.91B	$75.97B
2021-07-04	0.56	$39.04B	$70.32B
2021-04-04	0.57	$39.02B	$68.87B
2020-12-31	0.62	$39.14B	$63.47B
2020-09-27	0.79	$51.93B	$65.5B
2020-06-28	0.81	$52.01B	$64.57B
2020-03-29	0.56	$36.62B	$65.34B
2019-12-31	0.59	$37.42B	$63.45B
2019-09-29	0.59	$38.48B	$65.4B
2019-06-30	0.64	$38.31B	$59.92B
2019-03-31	0.68	$40.2B	$59.16B
2018-12-31	0.59	$37.69B	$63.76B
2018-09-30	0.53	$37.91B	$71.66B
2018-07-01	0.47	$33.2B	$70.12B
2018-04-01	0.52	$36.59B	$70.54B
2017-12-31	0.52	$37.08B	$71.66B
2017-10-01	0.61	$37.58B	$61.11B
2017-07-02	0.63	$37.26B	$58.69B
2017-04-02	0.67	$39.62B	$58.75B
2016-12-31	0.6	$35.62B	$59.84B
2015-12-31	0.5	$32.46B	$65B
2014-12-31	0.48	$34.55B	$71.62B
2013-12-31	0.42	$32.52B	$76.62B
2012-12-31	0.41	$33.49B	$81.68B
2011-12-31	0.42	$34.93B	$82.62B
2010-12-31	0.47	$41.91B	$88.27B
2009-12-31	0.48	$43.22B	$90.45B
2008-12-31	0.15	$8.9B	$57.74B

Annual Debt/Equity Ratio

Date	Debt/Equity Ratio	Long-term debt	Shareholder equity
2025-12-31	0.74	$64.64B	$86.78B
2024-12-31	0.69	$61.15B	$88.5B
2023-12-31	0.71	$63.79B	$89.29B
2022-12-31	0.37	$35.44B	$95.92B
2021-12-31	0.49	$37.83B	$77.46B
2020-12-31	0.62	$39.14B	$63.47B
2019-12-31	0.59	$37.42B	$63.45B
2018-12-31	0.59	$37.69B	$63.76B
2017-12-31	0.52	$37.08B	$71.66B
2016-12-31	0.6	$35.62B	$59.84B
2015-12-31	0.5	$32.46B	$65B
2014-12-31	0.48	$34.55B	$71.62B
2013-12-31	0.42	$32.52B	$76.62B
2012-12-31	0.41	$33.49B	$81.68B
2011-12-31	0.42	$34.93B	$82.62B
2010-12-31	0.47	$41.91B	$88.27B
2009-12-31	0.48	$43.22B	$90.45B
2008-12-31	0.15	$8.9B	$57.74B

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64